Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial
Not available.
Saved in:
Main Authors: | Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa Rimsza, Ahmad Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y. Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-07-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/12159 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stratification of Patients with Follicular Lymphoma
by: El-Ghaffar, Hasan A. Abd, et al.
Published: (2012) -
MicroRNA Expression in Follicular Lymphoma
by: Lawrie, Charles H.
Published: (2012) -
Editorial: Nanodrug delivery strategies for enhanced cancer chemo-immunotherapy
by: Yufen Xiao, et al.
Published: (2025-07-01) -
Modern approaches to the treatment of relapsed follicular lymphoma
by: Yu. E. Ryabukhina, et al.
Published: (2022-07-01) -
The effectiveness of chemo-radiotherapy programs of last generation in patients with hodgkin's lymphoma
by: E. A. Demina, et al.
Published: (2022-11-01)